Intravesical gemcitabine in superficial bladder tumors. Results of a phase I-II study

2004

the good tolerability of intravesical gemcitabine have been recently published. The evaluation of the activity on a papillary marker lesion is the best tool to measure the efficacy of a drug by intravesical route against superficial transitional cell carcinoma of the bladder (TCCB). The scientific background and the ethical acceptability of this approach have been validated by the European Organization for Research and Treatment of Cancer Urological Group. The aim of the present study was to evaluate the ablative efficacy of weekly intravesical instillations of gemcitabine against a histologically proven papillary marker lesion. MATERIAL & METHODS: Twenty-seven patients, affected by recurre…

Intravesical gemcitabine is superficial bladder tumours. Results of a phase I-II study

2004

-

Does hyperthermia improve the results of intravesical chemotherapy?

2004

Ipertermia e chemioterapia nel tumore vescicale superficiale a medio-alto rischio:esperienza preliminare sulla tollerabilità.

2004

Ruolo prognostico della p53 nel tumore vescicale superficiale. Correlazione con recidiva e progressione –

2005

-

INTRAVESICAL GEMCITABINE IN SUPERFICIAL BLADDER TUMOURS.RESULTS OF A PHASE I-II STUDY

2004

Studio clinico randomizzato, cross over, in aperto con Tadalafil per valutare uno schema ottimale di trattamento in pazienti con DE: nostra esperienza

2004

Risultati di uno studio piolota di fase I-II con gemcitabina endovescicale nel tumore vescicale superficiale (Ta-T1).

2004